UroStream

In recent years, with the advancements in targeted therapy and immunotherapy, significant progress has been made in the treatment of advanced renal cell carcinoma (RCC). Several large-scale phase III clinical trials involving targeted and immunotherapy combinations have been successful, marking the beginning of a new era in first-line treatment for advanced RCC. Following the successful 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association in Xi'an, Urology Frontier invited Dr. Hao Zeng from West China Hospital, Sichuan University, to share insights on unmet needs in advanced RCC, strategies for combining targeted and immunotherapy, management of adverse events, and future directions in treatment.

From August 8th to 11th, 2024, the Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi'an. The conference, organized by the Chinese Medical Doctor Association and the Urology Physicians Branch, and hosted by Xijing Hospital of the Air Force Medical University, with support from the Urology Physicians Branch of the Shaanxi Medical Doctor Association, showcased the latest achievements in urology from a broad and diverse perspective under the theme "Healthy China, Urology Leads the Way." On the first day of academic sessions (August 9th), Urology Frontier interviewed the honorary chairman of the conference, Dr. Liqun Zhou of Peking University First Hospital, who shared insights on the highlights of the conference, the current status of surgical robot development in urology, and provided guidance for the development of multidisciplinary team (MDT) treatment in grassroots hospitals.

From August 8-11, 2024, the Annual Meeting of the Chinese Urological Association (CUDA) was held in Xi'an, hosted by the Chinese Medical Doctor Association and its Urological Physician Branch, organized by Xijing Hospital of the Air Force Medical University, and co-hosted by the Urology Physician Branch of the Shaanxi Medical Doctor Association. Under the theme "Healthy China, Urology First," the conference showcased the latest advancements in urology from a broad perspective and multiple dimensions. On the first day of the academic sessions (August 9), Urology Frontier interviewed the conference host, Dr. Jianming Guo from Zhongshan Hospital affiliated with Fudan University, to share insights on the unmet clinical needs of prostate cancer in China, recent breakthroughs in clinical research, and future exploration directions.

Androgen deprivation therapy (ADT), also known as castration therapy, involves lowering male hormone levels through surgery or medication to treat prostate cancer. Recently, the 2024 Annual Meeting of the Chinese Urological Association (CUDA) was successfully held in Xi'an. Following the event, Urology Frontier invited Dr. Tao Xu, Director of Urology at Peking University People's Hospital, to share insights on the challenges and developments in prostate cancer androgen deprivation therapy.

From August 8th to 11th, 2024, the Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi'an. The conference was hosted by the Chinese Medical Doctor Association and the Urology Physicians Branch, organized by Xijing Hospital of the Air Force Medical University, and co-organized by the Urology Physicians Branch of the Shaanxi Medical Doctor Association. Under the banner of "Healthy China, Urology Takes the Lead," the conference brought together many of the latest achievements in urology. At the conference, Urology Frontier interviewed the conference's executive chairman, Dr. Weijun Qin of Xijing Hospital, Air Force Medical University, who summarized the conference's innovations and significance, and shared breakthroughs in xenotransplantation and advancements in prostate cancer diagnosis and treatment.

Prostate cancer is the most common malignancy of the male genitourinary system. Compared to Western countries, a larger proportion of prostate cancer patients in China are diagnosed at intermediate to advanced stages, leading to poorer prognosis. At the recent 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA), Urology Frontier invited Dr. Sujun Han from the National Cancer Center/Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, to discuss the background of the development of single-disease quality control indicators for prostate cancer, the value of promoting standardized diagnosis and treatment, and treatment strategies for advanced patients, with the goal of improving both survival rates and quality of life for prostate cancer patients.

In the journey toward a "Healthy China," urology leads the way. From August 9th to 11th, 2024, the eagerly anticipated 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association was grandly held in Xi'an. With a broad global perspective, the conference showcased the latest achievements in the field of urology from multiple angles, paving the way for a new chapter in China's healthcare construction alongside urology professionals nationwide. After the event, Urology Frontier had the honor of interviewing the conference chairman, Dr. Nianzeng Xing, Vice President of the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, who shared insights on the conference highlights, Chinese initiatives, and the training of young professionals.